Small Cell Lung Cancer This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest news and research items in this category.

Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer.
Conclusion. In this small series of SCLC patients treated with proton therapy with radical intent, treatment was well tolerated with no cases of acute grade 3+ esophagitis or acute grade 2+ pneumonitis. Dosimetric comparison showed better sparing of lung and esophagus with proton therapy. Proton therapy merits further investigation as a method of reducing the toxicity of CRT. PMID: 23438357 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Source: Acta Oncologica - February 26, 2013 Category: Cancer & Oncology Authors: Colaco RJ, Huh S, Nichols RC, Morris CG, D'Agostino H, Flampouri S, Li Z, Pham DC, Bajwa AA, Hoppe BS Tags: Acta Oncol Source Type: research

Does surgery improve prognosis in patients with small-cell lung carcinoma?
This study also discerned that no survival benefit was accrued by adding surgery to chemotherapy. However, this study only included patients who responded to an initial course of chemotherapy and also excluded patients with peripheral nodules only. Subsequent investigators have asserted the value of surgery in SCLC. A retrospective case–control study found that surgery significantly improved median survival in patients with stage I disease when compared with patients undergoing medical therapy. One British centre reported survival rates of 52% at 5 years amongst patients undergoing resection and nodal dissection for ...
Source: Interactive CardioVascular and Thoracic Surgery - February 11, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Jones, C. D., Cummings, I. G., Shipolini, A. R., McCormack, D. J. Tags: Thoracic Source Type: research

Ipilimumab in Combination With Paclitaxel and Carboplatin in SCLCIpilimumab in Combination With Paclitaxel and Carboplatin in SCLC
This study enrolled patients with ED-SCLC as well as those with advanced NSCLC. Results for the ED-SCLC cohort are presented here. Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 10, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells
Background: Small cell lung cancer (SCLC) is a special kind of lung cancers, lymph or blood metastasis of SCLC usually occurs in early stage. Studies in breast and colon cancer showed over expression of SATB1 could promote tumor cell growth and inhibit apoptosis. Therefore, we studied the expression of SATB1 in SCLC. Methods: The level of SATB1 was analyzed in SCLC tissues, metastatic lymphoid nodes and adjacent normal lung tissues by immunohistochemistry. Meanwhile, small interfering SATB1-targeting RNA was constructed and transfected into human SCLC cell line NCI-H446 to evaluate the effects of SATB1-siRNA on cell prolif...
Source: Cancer Cell International - February 5, 2013 Category: Cancer & Oncology Authors: Bo HuangHongli ZhouXiaodong WangZhiliang Liu Source Type: research

Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study.
CONCLUSION: Improvement in the 3-month PFS after treatment with topotecan-bevacizumab was promising compared with the historical control and justifies additional studies with this regimen. PMID: 23391616 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 4, 2013 Category: Cancer & Oncology Authors: Spigel DR, Waterhouse DM, Lane S, Legenne P, Bhatt K Tags: Clin Lung Cancer Source Type: research

Cerulean doses first patient in Phase 2 study of small cell lung cancer drug
US based clinical-stage company Cerulean Pharma has dosed the first patient in a randomised Phase 2 study of its anti-cancer drug for treating extensive-stage small cell lung cancer (SCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - February 3, 2013 Category: Pharmaceuticals Source Type: news

Clinicopathological and prognostic significance of HIF-1α and HIF-2α expression in small cell lung cancer.
Abstract Previous work from our laboratory has demonstrated that urokinase plasminogen activator receptor (uPAR) may be a potential stem-like cell marker in SCLC. Hypoxia inducible factor (HIF) has been shown to transcriptionally regulate uPAR expression. Therefore, the aim of this study was to evaluate the relationship between HIF-1α/HIF-2α and uPAR expression, and to investigate the role of HIF-1α/HIF-2α in the clinical pathology and prognosis of patients with SCLC. Immunohistochemical analysis showed that HIF-1α/HIF-2α staining was mainly present in the nuclei of cancer cells. HIF-1α-positive cells were d...
Source: Pathology, Research and Practice - January 31, 2013 Category: Pathology Authors: Luan Y, Gao C, Miao Y, Li Y, Wang Z, Qiu X Tags: Pathol Res Pract Source Type: research

A Randomized Controlled Study of Chemotherapy:  Etoposide Combined with Oxaliplatin or Cisplatin Regimens in the Treatment  of Extensive-stage Small Cell Lung Cancer in Elderly Patients
This study aims to compare the efficacy and toxicities between etoposide plus oxaliplatin (EO) and etoposide plus cisplatin (EP) regimens as first-line chemotherapy for elderly patients with SCLC. Methods Seventy-one old, extensive-stage SCLC patients, who had not received anti-tumor treatment, were randomly divided into two groups, namely, EO group (etoposide: 80 mg/m2 d1-5+oxaliplatin; 130 mg/m2 d1; repeated every 21 days) and EP group (etoposide: 80 mg/m2 d1-5+cisplatin; 25 mg/m2 d1-3; repeated every 21 days). Efficacy and toxicities were evaluated after 2 or more cycles. Results No statistical differences were observed...
Source: Chinese Journal of Lung Cancer - January 17, 2013 Category: Cancer & Oncology Source Type: research

Present role of prophylactic cranial irradiation.
Abstract Prophylactic cranial irradiation (PCI) plays a role in the management of lung cancer patients, especially small cell lung cancer (SCLC) patients. As multimodality treatments are now able to ensure better local control and a lower rate of extracranial metastases, brain relapse has become a major concern in lung cancer. As survival is poor after development of brain metastases (BM) in spite of specific treatment, PCI has been introduced in the 1970's. PCI has been evaluated in randomized trials in both SCLC and non-small cell lung cancer (NSCLC) to reduce the incidence of BM and possibly increase survival. P...
Source: Bulletin du Cancer - January 11, 2013 Category: Cancer & Oncology Authors: Le Péchoux C, Al Mohkles H, Dhermain F Tags: Bull Cancer Source Type: research

TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma
In conclusion, BDNF/TrkB signal is involved in malignant progression of invasiveness and tumorigenicity for LCNEC, and may be a potential target for LCNEC without standard therapy. (Source: Lung Cancer)
Source: Lung Cancer - January 10, 2013 Category: Cancer & Oncology Authors: Seiichi Odate, Katsuya Nakamura, Hideya Onishi, Masayuki Kojima, Akihiko Uchiyama, Kenji Nakano, Masato Kato, Masao Tanaka, Mitsuo Katano Tags: Carcinogenesis and molecular biology Source Type: research

Nesfatin-1 in advanced lung cancer patients with weight loss.
In conclusion, loss of fat mass may decrease serum nesfatin-1 level in lung cancer patients with weight loss. The future studies which explore biological significance of low serum nesfatin-1 level in cancer are needed. PMID: 23269222 [PubMed - as supplied by publisher] (Source: Regulatory Peptides)
Source: Regulatory Peptides - December 23, 2012 Category: Biochemistry Authors: Cetinkaya H, Karagöz B, Bilgi O, Ozgün A, Tunçel T, Emirzeoğlu L, Top C, Kandemir EG Tags: Regul Pept Source Type: research

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
Conclusion These results suggest further investigation of ipilimumab in ED-SCLC. (Source: Annals of Oncology)
Source: Annals of Oncology - December 18, 2012 Category: Cancer & Oncology Authors: Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J. - M., Lynch, T. J. Tags: lung cancer Source Type: research

Stimulation of the chemosensory TRPA1 cation channel by volatile toxic substances promotes cell survival of small cell lung cancer cells.
Abstract TRPA1, a member of the transient receptor potential (TRP) family of cation channels, has mainly been characterized as a chemosensory protein in neuronal cells. TRPA1 is activated by toxic or irritating volatile agents like allyl isothiocyanate (AITC), tear gas, formalin, or cigarette smoke. To date, little is known about a function of TRPA1 in non-neuronal cells in the respiratory system and even less regarding a possible role in cancer biology. Here, we show that TRPA1 is expressed in a panel of human small cell lung cancer (SCLC) cell lines. Of note, TRPA1 mRNA was also significantly higher expressed in ...
Source: Biochemical Pharmacology - December 5, 2012 Category: Drugs & Pharmacology Authors: Schaefer EA, Stohr S, Meister M, Aigner A, Gudermann T, Buech TR Tags: Biochem Pharmacol Source Type: research

Survivin expression impacts prognostically on NSCLC but not SCLC
Abstract: Survivin is expressed in lung cancer and in most cancer tissues and has a significant impact on prognosis. This work aimed to comparatively assess survivin expression and significance in Non-Small (NSCLC) and Small Cell Lung Cancers (SCLC). Sixty-five NSCLC and 35 SCLC samples were analyzed by semi-quantitative real-time RT-PCR. Survivin mRNA levels were significantly higher in tumors than in normal tissue, and in SCLC than in NSCLC samples. Immunohistochemistry and FISH analyses were performed in 59 and 26 tumor specimens, respectively. In SCLC survivin was only present in cytoplasm, while in some NSCLC cases it...
Source: Lung Cancer - December 5, 2012 Category: Cancer & Oncology Authors: Antonio Rosato, Chiara Menin, Daniela Boldrin, Silvia Dalla Santa, Laura Bonaldi, Maria Chiara Scaini, Paola Del Bianco, Davide Zardo, Matteo Fassan, Rocco Cappellesso, Ambrogio Fassina Tags: Clinical correlates Source Type: research

A retrospective analysis of survival outcomes for two different radiotherapy fractionation schedules given in the same overall time for limited stage small cell lung cancer
ConclusionsGiven the small sample size, the potential for selection bias and the retrospective nature of our study it is not possible to draw firm conclusions regarding the efficacy of hypofractionated thoracic radiotherapy compared with hyperfractionated accelerated thoracic radiotherapy however hypofractionated radiotherapy may result in equivalent relapse‐free survival. (Source: Australasian Radiology)
Source: Australasian Radiology - December 1, 2012 Category: Radiology Authors: Catherine S Bettington, Lee Tripcony, Guy Bryant, Brigid Hickey, Gary Pratt, Michael Fay Tags: Radiation Oncology—Original Article Source Type: research

Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection
& U Schumacher (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - November 30, 2012 Category: Cancer & Oncology Authors: T WunderK SchmidD WickleinP GroitlT DobnerT LangeM AndersU Schumacher Tags: coxsackie adenovirus receptor (CAR) oncolytic therapy small cell lung cancer (SCLC) neuroendocrine lung cancer histone deacetylase inhibitors Source Type: research

Functional screen for secreted proteins by monoclonal antibody library and identification of Mac-2 binding protein as a potential therapeutic target and biomarker for lung cancer.
In this study, we developed a novel strategy that combined functional monoclonal antibody library screening technique and mass spectrometry to identify functional secreted proteins. BALB/c mice were immunized with cancer cells isolated from fresh human lung cancer tissues. The monoclonal antibody library containing 1160 mAbs was established with the mouse spleen cells, whose serum had most anti-proliferative effect on lung cancer cells. Monoclonal antibodies were subjected to an immunoreactive and functional screen and monoclonal antibodies that reacted strongly with secreted proteins in condition medium and lung cancer ti...
Source: Molecular and Cellular Proteomics : MCP - November 26, 2012 Category: Molecular Biology Authors: Sun L, Chen L, Sun L, Pan J, Yu L, Han L, Yang Z, Luo Y, Ran Y Tags: Mol Cell Proteomics Source Type: research

PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma
Conclusion: PTPRZ1 was highly expressed in human NET tissues and PTPRZ1 is an oncogenic tyrosine phosphatase in SCLCs. These results imply that a new signaling pathway involving PTPRZ1 could be a feasible target for treatment of NETs. (Source: BMC Cancer)
Source: BMC Cancer - November 21, 2012 Category: Cancer & Oncology Authors: Hideki MakinoshimaGenichiro IshiiMotohiro KojimaSatoshi FujiiYouichi HiguchiTakeshi KuwataAtsushi Ochiai Source Type: research

Targeting the Phosphoinositide 3-Kinase p110α Isoform Impairs Cell Proliferation, Survival and Tumor Growth in Small Cell Lung Cancer.
CONCLUSIONS: Together our data demonstrate the key involvement of the PI3K isoform p110α in the regulation of multiple tumor-promoting processes in SCLC. PMID: 23172887 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - November 21, 2012 Category: Cancer & Oncology Authors: Wojtalla A, Fischer B, Kotelevets N, Mauri FA, Sobek J, Rehrauer H, Wotzkow C, Tschan M, Seckl MJ, Zangemeister-Wittke U, Arcaro A Tags: Clin Cancer Res Source Type: research

A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer
Conclusions: Although tumor response was noted in 2 patients, the median PFS was short and most patients were unable to tolerate the treatment. At the current dose schedule, sunitinib does not appear to warrant further evaluation. (Source: Lung Cancer)
Source: Lung Cancer - November 21, 2012 Category: Cancer & Oncology Authors: Ji-Youn Han, Hyae Young Kim, Kun Young Lim, Jong Hee Han, You Jin Lee, Mi Hyang Kwak, Hak Jin Kim, Tak Yun, Heung Tae Kim, Jin Soo Lee Tags: Treatment Source Type: research

Concurrent chemo-radiotherapy confirmed best for limited SCLC
NEW YORK (Reuters Health) - Patients with limited small-cell lung cancer (SCLC) survive longer when chemotherapy and radiotherapy are given concurrently rather than sequentially, a Polish team reports. (Source: Modern Medicine)
Source: Modern Medicine - November 20, 2012 Category: Journals (General) Source Type: news

Dysphagia in a Patient With Recurrent Small-Cell Lung Cancer
Question: A 67-year-old woman with a neuroendocrine small-cell lung cancer (SCLC), recurrent after chemotherapy and radiation therapy, complained of recent-onset dysphagia. She has noticed regurgitation of liquids and some solid-food dysphagia. She has lost 20 pounds in the past 2 months. She has no past history of gastroesophageal reflux symptoms or esophagitis. Physical examination reveals no significant abnormalities, but she had had a peripheral sensory neuropathy that improved with treatment of her SCLC. Laboratory tests are unremarkable except for a positive Hu immunoglobulin (Ig)G serum anti-neuronal nuclear antibod...
Source: Gastroenterology - November 19, 2012 Category: Gastroenterology Authors: William R. Brown, Elizabeth Dee Tags: Clinical Challenges and Images in GI Source Type: research

Clinical outcomes of reirradiation of brain metastases from small cell lung cancer with Cyberknife stereotactic radiosurgery
Conclusions: SRS for reirradiation of brain metastases from SCLC is safe and achieves local tumor control in the majority of patients. Despite SRS, these patients are at high risk of distant brain failure. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - November 17, 2012 Category: Cancer & Oncology Authors: Adam C OlsonRodney E WegnerJean Claude M RwigemaDwight E HeronSteven A BurtonArlan H Mintz Source Type: research

Snail promotes an invasive phenotype in lung carcinoma
Conclusions: The results show that snail plays an important role in the invasive characteristics of lung carcinoma influencing the survival of the patients. Snail knockdown might thus be one option for targeted molecular therapy in lung cancer. Snail knockdown influenced the expression of claudins individually in a cell-line dependent manner but did not influence MMP expressions or activations to any significant degree. (Source: Respiratory Research)
Source: Respiratory Research - November 17, 2012 Category: Respiratory Medicine Authors: Heta MerikallioTaina Turpeenniemi-HujanenPaavo PääkköRiitta MäkitaroKaarteenaho RSirpa SaloTuula SaloTerttu HarjuYlermi Soini Source Type: research

Pulmonary neuroendocrine tumors: An entity in search of cytologic criteria
In this study, we reviewed histologically confirmed 18 TC, 8 AC, 10 LCNEC, and 10 SCLC cytologic specimens from 45 patients. The following features were reviewed: small clusters, geographic sheets, trabecular structures, pseudo‐rosettes, single cells, doublets, triplets or short cords, papillary‐like structures, capillary vasculatures, necrosis, smear background, cell size, cell pleomorphism, amount of cytoplasm, plasmacytoid cells, spindle cells, nuclear atypia, molding, palisading and smearing, chromatin textures, nucleoli, and mitotic figure count. Based on our results, geographic clusters and necrosis were often se...
Source: Diagnostic Cytopathology - November 16, 2012 Category: Pathology Authors: Cheng Cheng Huang, Brian T. Collins, Andrew Flint, Claire W. Michael Tags: Original Article Source Type: research

Aurora kinase inhibitors effective in SCLC patients with MYC amplification
Sos ML. Proc Natl Acad Sci USA. 2012;109:17034-17039. (Source: HemOncToday.com)
Source: HemOncToday.com - November 14, 2012 Category: Cancer & Oncology Source Type: news

The influence of time of radio-chemotherapy and other therapeutic factors on treatment results in patients with limited disease small cell lung cancer
Conclusions: The concurrent chemo-radiotherapy with early administration of thoracic radiotherapy, results in improved complete response in the thorax and increase of overall and disease-free survival rates. The 5-year survival rates were: 17.7% for overall survival and 19.3% for disease-free survival. Our analysis and data from the literature suggest that shorter SER may play prognostic role in patients with LD SCLC treated with combination chemo- and radiotherapy. However, these observations require the confirmation in following studies. (Source: Lung Cancer)
Source: Lung Cancer - November 14, 2012 Category: Cancer & Oncology Authors: Beata Sas-Korczynska, Andrzej Sokolowski, Stanislaw Korzeniowski Tags: Treatment Source Type: research

Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis
Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. Content Type Journal ArticleCategory Research ArticlePages 1-6DOI 10.1007/s12094-012-0960-6Authors T. Korkmaz, Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, žemsi Denizer Cad. E-5 Karayolu Cevizli Mevkii, 34890 Kartal/Istanbul, TurkeyS. Seber, Medical Oncology Department, Marmara University Hospital, Istanbul, TurkeyU. Kefeli, Department of Medical Oncology, Dr. Lutfi Kirdar Kar...
Source: Clinical and Translational Oncology - November 9, 2012 Category: Cancer & Oncology Tags: Clinical and Translational Oncology Source Type: research

Treatment Update in Small-Cell Lung Cancer: From Limited to Extensive Disease
Opinion statement Small-cell lung cancers are aggressive tumors, often discovered with widespread metastases that include brain involvement. For patients with limited-stage disease, the standard of care is platinum-doublet chemotherapy (often etoposide) with concurrent radiation. Concurrent chemoradiotherapy can be difficult when given upfront, sometimes preventing on-time completion of later chemotherapy cycles. Recent data support giving concurrent chemoradiotherapy following 1 or 2 cycles of chemotherapy alone. For patients with extensive disease, chemotherapy alone remains the standard of care. For patie...
Source: Current Treatment Options in Oncology - November 8, 2012 Category: Cancer & Oncology Tags: Current Treatment Options in Oncology Source Type: research

Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer
Conclusion NP with CPT is effective and safe for patients with ED-SCLC. Content Type Journal ArticleCategory Original ArticlePages 1-6DOI 10.1007/s00280-012-2011-yAuthors Fumihiro Oshita, Department of Thoracic Oncology Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Yokohama, 241-0815 JapanMakiko Sugiura, Department of Thoracic Oncology Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Yokohama, 241-0815 JapanShuji Murakami, Department of Thoracic Oncology Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Yokohama, 241-0815 JapanTetsuro Kondo, Department of Thoracic Oncology Kanagawa Cancer Center, Nakao 1-1-...
Source: Cancer Chemotherapy and Pharmacology - November 2, 2012 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: research

TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival
Summary TIMELESS (TIM) is a mammalian homolog of a Drosophila circadian rhythm gene, but its circadian properties in mammals have yet to be determined. TIM appears to be essential for replication protection and genomic stability. Recently, the involvement of TIM in human malignancies has been reported, and thus we investigated the role of TIM in lung cancer. Microarray expression analysis of lung cancer cell lines showed that TIM expression was elevated by 3.7‐fold (P < 0.001) in non‐small cell lung cancer (NSCLC) cell lines (n=116) compared to normal lung controls (n=59). In addition, small cell lung cancer (SCLC) ...
Source: Cancer Science - November 1, 2012 Category: Cancer & Oncology Authors: Kenya Yoshida, Mitsuo Sato, Tetsunari Hase, Momen Elshazley, Ryo Yamashita, Noriyasu Usami, Tetsuo Taniguchi, Kohei Yokoi, Shigeo Nakamura, Masashi Kondo, Luc Girard, John. D. Minna, Yoshinori Hasegawa Tags: Original Article Source Type: research

Correlation of Apparent Diffusion Coefficient with Histologic Type and Grade of Lung Cancer
Conclusion ADC value is significant for judgement of histologic type and grade of lung cancer before surgical operation: SCLC has a low ADC value, and ADC value is low for the tumor with poorly-differentiated grade. (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - October 24, 2012 Category: Cancer & Oncology Source Type: research

Prophylactic cranial irradiation in small-cell lung cancer: Findings from a North Central Cancer Treatment Group Pooled Analysis
Conclusions PCI was associated with a significant survival benefit for both ESCLC and LSCLC patients who had SD or a better response to chemotherapy ± TRT. Dose fractionation appears important. PCI was associated with an increase in overall and specific grade 3+ AE rates. (Source: Annals of Oncology)
Source: Annals of Oncology - October 22, 2012 Category: Cancer & Oncology Authors: Schild, S. E., Foster, N. R., Meyers, J. P., Ross, H. J., Stella, P. J., Garces, Y. I., Olivier, K. R., Molina, J. R., Past, L. R., Adjei, A. A., on behalf of North Central Cancer Treatment Group Tags: lung cancer Source Type: research

Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor
Conclusion Absolute CTCs after one cycle of chemotherapy in patients with SCLC is the strongest predictor for response on chemotherapy and survival. Patients with low initial CTC numbers lived longer than those with higher CTCs. (Source: Annals of Oncology)
Source: Annals of Oncology - October 22, 2012 Category: Cancer & Oncology Authors: Hiltermann, T. J. N., Pore, M. M., van den Berg, A., Timens, W., Boezen, H. M., Liesker, J. J. W., Schouwink, J. H., Wijnands, W. J. A., Kerner, G. S. M. A., Kruyt, F. A. E., Tissing, H., Tibbe, A. G. J., Terstappen, L. W. M. M., Groen, H. J. M. Tags: lung cancer Source Type: research

Systematic review of β-Elemene injection as adjunctive treatment for lung cancer
Conclusions The effectiveness of chemotherapy for the treatment of lung cancer may improve when combined with β-elemene injection as an adjunctive treatment. The combined treatment can result in an improved quality of life and prolonged survival. However, these results require confirmation by rigorously controlled trials. Content Type Journal ArticleCategory Original ArticlePages 813-823DOI 10.1007/s11655-012-1271-9Authors Bin Wang, School of Public Health and Family Medicine, Capital Medical University, Beijing, 100069 ChinaXiao-xia Peng, School of Public Health and Family Medicine, Capital Medica...
Source: Chinese Journal of Integrative Medicine - October 20, 2012 Category: Internal Medicine Tags: Chinese Journal of Integrative Medicine Source Type: research

A Comparative Analysis of Radiobiological Models for Cell Surviving Fractions at High Doses.
Abstract For many years the linear-quadratic (LQ) model has been widely used to describe the effects of total dose and dose per fraction at low-to-intermediate doses in conventional fractionated radiotherapy. Recent advances in stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) have increased the interest in finding a reliable cell survival model, which will be accurate at high doses, as well. Different models have been proposed for improving descriptions of high dose survival responses, such as the Universal Survival Curve (USC), the Kavanagh-Newman (KN) and several generalizations of the LQ model...
Source: Technology in Cancer Research and Treatment - October 19, 2012 Category: Cancer & Oncology Authors: Andisheh B, Edgren M, Belkic D, Mavroidis P, Brahme A, Lind BK Tags: Technol Cancer Res Treat Source Type: research

Actionable targets in small cell lung cancer [Medical Sciences]
Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. The prognosis of SCLC patients is devastating and no biologically targeted therapeutics are active in this tumor type. To develop a framework for development of specific SCLC-targeted drugs we conducted a combined genomic and pharmacological vulnerability screen... (Source: Proceedings of the National Academy of Sciences)
Source: Proceedings of the National Academy of Sciences - October 16, 2012 Category: Science Authors: Sos, M. L., Dietlein, F., Peifer, M., Schottle, J., Balke–Want, H., Muller, C., Koker, M., Richters, A., Heynck, S., Malchers, F., Heuckmann, J. M., Seidel, D., Eyers, P. A., Ullrich, R. T., Antonchick, A. P., Vintonyak, V. V., Schneider, P. M., Nin Tags: Biological Sciences Source Type: research

Efficacy and limitations of salvage gamma knife radiosurgery for brain metastases of small-cell lung cancer after whole-brain radiotherapy
Conclusions GKS may be an effective option for controlling SCLC-associated brain metastases after WBRT and for preventing neurological death in patients without carcinomatous meningitis. Content Type Journal ArticleCategory Clinical ArticlePages 1-8DOI 10.1007/s00701-012-1520-0Authors Kiyoshi Nakazaki, Department of Neurosurgery, Brain Attack Center, Ota Memorial Hospital, 3-6-28 Okinogami, Fukuyama, Hiroshima 720-0825, JapanYoshinori Higuchi, Department of Neurological Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba 260-8677, JapanOsamu Nagano, Gamma Knife House, Ch...
Source: Acta Neurochirurgica - October 12, 2012 Category: Neurology Tags: Acta Neurochirurgica Source Type: research

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin
Abstract: Background: Small cell lung cancer (SCLC) is associated with poor prognosis due to its early metastatic potential and lack of improved outcomes with newer cytotoxic agents. Identifying factors associated with clinical outcomes can help clinicians determine which patients are more likely to benefit from therapy. Functional Assessment of Cancer Therapy (FACT) subscales and Eastern Cooperative Oncology Group performance status (ECOG PS) were retrospectively analyzed as prognostic factors for overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage disease (ED)-SCLC.Methods: Using da...
Source: Lung Cancer - October 8, 2012 Category: Cancer & Oncology Authors: Martin Reck, Nick Thatcher, Egbert F. Smit, Paul Lorigan, Ewa Szutowicz-Zielinska, Astra M. Liepa, Katherine B. Winfree, Patrick Peterson, Susan C. Guba, Mark A. Socinski Tags: Quality of life Source Type: research

Effect of a large hole reservoir on the charge transport in TiO2/organic hybrid devices
Phys. Chem. Chem. Phys., 2012, 14,14186-14189DOI: 10.1039/C2CP41543G, CommunicationSimon Sanden, Oskar Sandberg, Qian Xu, Jan-Henrik Smatt, Gytis Juska, Mika Linden, Ronald OsterbackaHole accumulation at the TiO2/P3HT:PCBM interface is observed at negative offset voltages, leading to SCLC extraction.The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Phys. Chem. Chem. Phys. latest articles)
Source: RSC - Phys. Chem. Chem. Phys. latest articles - October 7, 2012 Category: Chemistry Authors: Simon Sanden Source Type: research

New Targeted Therapy Indicated By Breakthrough In Understanding Lung Cancer Vulnerabilities
More effective treatments for one of the deadliest forms of cancer are one step closer thanks to groundbreaking research from an international collaborative study. Scientists from the Universities of Sheffield and Cologne have identified the dependencies of multiple Small Cell Lung Cancer (SCLC) types - paving the way for clinical trials of new targeted treatments which could revolutionise the current approach. Around 40,000 people are diagnosed annually with lung cancer in the UK, and SCLC accounts for nearly one in five of all these cases... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 4, 2012 Category: Consumer Health News Tags: Lung Cancer Source Type: news

Two MicroRNA Panels to Discriminate Three Subtypes of Lung Carcinoma in Bronchial Brushing Specimens.
CONCLUSION: We found 2 microRNA panels that accurately discriminated between the 3 subtypes of lung carcinoma in bronchial brushing specimens. The identified microRNA panels may have considerable clinical value in differential diagnosis and optimizing treatment strategies based on lung cancer subtypes. PMID: 23043084 [PubMed - as supplied by publisher] (Source: American Journal of Respiratory and Critical Care Medicine)
Source: American Journal of Respiratory and Critical Care Medicine - October 4, 2012 Category: Respiratory Medicine Authors: Huang W, Hu J, Yang DW, Fan XT, Jin Y, Hou YY, Wang JP, Yuan YF, Tan YS, Zhu XZ, Bai CX, Wu Y, Zhu HG, Lu SH Tags: Am J Respir Crit Care Med Source Type: research

Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma
Abstract Lung cancer is the worldwide leading cause of death from cancer and has been shown to be a heterogeneous disease at the genomic level. To delineate the genomic landscape of copy number alterations, amplifications, loss‐of‐heterozygosity, tumor ploidy and copy‐neutral allelic imbalance in lung cancer, microarray‐based genomic profiles from 2141 tumors and cell lines including adenocarcinomas (AC, n=1206), squamous cell carcinomas (SqCC, n=467), large cell carcinomas (LCC, n=37) and small cell lung carcinomas (SCLC, n=88) were assembled from different repositories. Copy number alteration differences between ...
Source: International Journal of Cancer - October 1, 2012 Category: Cancer & Oncology Authors: Johan Staaf, Sofi Isaksson, Anna Karlsson, Mats Jönsson, Leif Johansson, Per Jönsson, Johan Botling, Patrick Micke, Bo Baldetorp, Maria Planck Tags: Cancer Genetics Source Type: research

Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy
Abstract: Histopathological samples are commonly used for molecular testing to detect both oncogenes and tumor-suppressor genes in lung cancer. The purpose of this study was to determine the efficacy of using curette lavage fluid for molecular testing to detect EGFR, KRAS and P53 mutations in lung cancer patients. Samples were obtained from 77 lung cancer patients by bronchoscopy at the time of diagnosis, collected by scraping the site of the primary tumor lesion with a curette. DNA was extracted from cells in the curette lavage fluid, and PCRs were performed to amplify mutation hot spot regions in the EGFR, KRAS and P53 g...
Source: Lung Cancer - October 1, 2012 Category: Cancer & Oncology Authors: Fumihiro Yamaguchi, Satoshi Kugawa, Hidetsugu Tateno, Fumio Kokubu, Kunihiko Fukuchi Tags: Diagnosis and pathology Source Type: research

Subpopulation of small‐cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy
In conclusion, both CD133 and CD87 proved to be inadequate markers for CSCs; however, they might be beneficial for predicting resistance to chemotherapy. (Source: Cancer Science)
Source: Cancer Science - October 1, 2012 Category: Cancer & Oncology Authors: Toshio Kubo, Nagio Takigawa, Masahiro Osawa, Daijiro Harada, Takashi Ninomiya, Nobuaki Ochi, Eiki Ichihara, Hiromichi Yamane, Mitsune Tanimoto, Katsuyuki Kiura Tags: Original Article Source Type: research

Factors affecting 30-month survival in lung cancer patients.
Abstract Background & objectives: Age adjusted incidence rate of lung cancer in India ranges from 7.4 to 13.1 per 100,000 among males and 3.9 to 5.8 per 100,000 among females. The factors affecting survival in lung cancer patients in India are not fully understood. The current study was undertaken to evaluate the factors affecting survival in patients diagnosed with lung cancer attending a tertiary care cancer institute in Bangalore, Karnataka, India. Methods: Consecutive patients with primary lung cancer attending Bangalore Institute of Oncology, a tertiary care centre at Bangalore, between 2006 and 2009 were...
Source: The Indian Journal of Medical Research - October 1, 2012 Category: Biomedical Science Authors: Mahesh PA, Archana S, Jayaraj BS, Patil S, Chaya SK, Shashidhar HP, Sunitha BS, Prabhakar AK Tags: Indian J Med Res Source Type: research

CD43 in the nucleus and cytoplasm of lung cancer is a potential therapeutic target
Abstract CD43 is a transmembrane sialoglycoprotein. Normally the molecule is only produced by white blood cells where it regulates functions such as intercellular adhesion, intracellular signaling, apoptosis, migration and proliferation. Two CD43 antibodies were used to interrogate 66 cases of non small cell lung cancer (NSCLC) and 24 cases of small cell lung cancer (SCLC). In addition, we engineered the CD43‐positive lung cancer cell line A549 to stably express either non‐targeted or CD43‐targeted small‐interfering RNA (siRNA). These lines were then subjected to in vitro assays of apoptosis, natural killer (NK) ce...
Source: International Journal of Cancer - September 27, 2012 Category: Cancer & Oncology Authors: Qiangwei Fu, Steven E. Cash, Jeremiah J. Andersen, Colin R. Kennedy, Darby G. Oldenburg, Valerie B. Zander, Greta R. Foley, Carl Simon Shelley Tags: Cancer Cell Biology Source Type: research

Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment
In this study, the action of MSP on the production of metastases was determined in a multiple-organ metastasis model. The murine MSP gene was transfected into two human SCLC cell lines, SBC-5 and H1048, to establish transfectants secreting biologically active MSP. MSP gene transduction did not affect cell proliferation and motility in vitro. Intravenously inoculated MSP transfectants produced significantly larger numbers of liver metastases than parental cells or vector control clones, while there were no significant differences in bone or lung metastases among them. Immunohistochemical analyses of liver metastases re...
Source: Clinical and Experimental Metastasis - September 26, 2012 Category: Cancer & Oncology Tags: Clinical and Experimental Metastasis Source Type: research

Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer
Conclusion Irinotecan plus cisplatin with concurrent split-course thoracic radiotherapy was effective and tolerable in untreated LD-SCLC. Content Type Journal ArticleCategory Original ArticlePages 1-7DOI 10.1007/s00280-012-1952-5Authors Minoru Fukuda, Department of Chemotherapy, Japanese Red Cross Nagasaki Genbaku Hospital, 3-15 Mori-machi, Nagasaki, 852-8511 JapanYoichi Nakamura, Second Department of Internal Medicine, Nagasaki University Hospital, Nagasaki, JapanAkitoshi Kinoshita, Department of Internal Medicine, Nagasaki Prefecture Shimabara Hospital, Nagasaki, JapanYoshifumi Soejima, Department of ...
Source: Cancer Chemotherapy and Pharmacology - September 25, 2012 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: research

Genetic association with overall survival of taxane-treated lung cancer patients - A genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study
Background: Taxane is one of the first line treatments of lung cancer. In order to identify novel single nucleotide polymorphisms (SNPs) that might contribute to taxane response, we performed a genome-wide association study (GWAS) for two taxanes, paclitaxel and docetaxel, using 276 lymphoblastoid cell lines (LCLs), followed by genotyping of top candidate SNPs in 874 lung cancer patient samples treated with paclitaxel. Methods: GWAS was performed using 1.3 million SNPs and taxane cytotoxicity IC50 values for 276 LCLs. The association of selected SNPs with overall survival in 76 small or 798 non-small cell lung cancer (SCLC...
Source: BMC Cancer - September 24, 2012 Category: Cancer & Oncology Authors: Nifang NiuDaniel SchaidRyan AboKrishna KalariBrooke FridleyQiping FengGregory JenkinsAnthony BatzlerAbra BrisbinJulie CunninghamLiang LiZhifu SunPing YangLiewei Wang Source Type: research